Physician profile
Anders Petersen
NPI 1902049836
$2,004.48
in general payments reported to CMS, 2019-2025
21 companies · $589 in 2025
The $589 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.22 · 2020: $13.02 · 2021: $67.83 · 2022: $372 · 2023: $500 · 2024: $407 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Entertainment: $13.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.74 |
| Entertainment | $13.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $689.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $323.37 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $138.58 | 2022-2025 | |
| Abbvie INC. | $135.33 | 2021-2023 | |
| Amgen INC. | $124.06 | 2020-2025 | Otezla, Repatha, Otezla |
| Medtronic, INC. | $115.80 | 2023-2025 | Intellis Adaptivestim, Inceptiv, Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $86.03 | 2022-2024 | Camzyos, Eliquis |
| Pfizer INC. | $75.73 | 2019-2025 | |
| Dexcom, INC. | $58.99 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $39.29 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.09 | 2019-2024 | Jardiance |
| Lundbeck LLC | $25.90 | 2023 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $25.44 | 2023 | Nuedexta |
| Xeris Pharmaceuticals, INC. | $21.37 | 2024 | Gvoke Hypopen |
| Mannkind Corporation | $19.04 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.59 | 2024 | Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $17.14 | 2021 | |
| Merck Sharp & Dohme LLC | $16.00 | 2023 | Belsomra |
| Astrazeneca Pharmaceuticals Lp | $15.35 | 2024 | Farxiga |
| Antares Pharma, INC. | $14.54 | 2022 | |
| Optos, INC. | $13.91 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anders Petersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.